In this study, a score based on glycosaminoglycan (GAG) profiling in subjects with suspicion of renal cell carcinoma (RCC) is hypothesized to distinguish malignant masses when early actionable clinical decisions are desirable. For example to diagnose early recurrence after surgical treatment; to screen population at risk of RCC; or to distinguish benign masses from RCC before surgical treatment. To this end, plasma and urine GAGs will be measured in a prospective cohort of patients referred to surgical treatment for RCC. The resulting GAG scores are then correlated to post-surgical recurrence, to post-surgical definitive diagnosis and and to tumor size if RCC. In a subset cohort of patients at high risk of RCC recurrence, plasma and urine GAGs will be monitored to observe its correlation with disease recurrence.

Inclusion Criteria:

• Patients referred for partial or radical nephrectomy for suspicion of renal cell carcinoma
• Predicted life expectancy over 2 months
• Standard imaging evaluation 12 weeks prior to inclusion
• Planned for standard imaging within 16 weeks after start of therapy

Exclusion Criteria:

• Lack of proper compliance to accept continuous samplings.

Subjects referred for partial or radical nephrectomy for suspicion of renal cell carcinoma

Data will be accessible upon study publication